{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["102(10)"],"submitter":["Mateos MV"],"pubmed_abstract":["Prior treatment exposure in patients with relapsed/refractory multiple myeloma may affect outcomes with subsequent therapies. We analyzed efficacy and safety according to prior treatment in the phase 3 TOURMALINE-MM1 study of ixazomib-lenalidomide-dexamethasone (ixazomib-Rd) <i>versus</i> placebo-Rd. Patients with relapsed/refractory multiple myeloma received ixazomib-Rd or placebo-Rd. Efficacy and safety were evaluated in subgroups defined according to type (proteasome inhibitor [PI] and immunomodulatory drug) and number (1 <i>vs.</i> 2 or 3) of prior therapies received. Of 722 patients, 503 (70%) had received a prior PI, and 397 (55%) prior lenalidomide/thalidomide; 425 patients had received 1 prior therapy, and 297 received 2 or 3 prior therapies. At a median follow up of ~15 months, PF"],"journal":["Haematologica"],"pagination":["1767-1775"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC5622861"],"repository":["biostudies-literature"],"pubmed_title":["Impact of prior therapy on the efficacy and safety of oral ixazomib-lenalidomide-dexamethasone <i>vs</i>. placebo-lenalidomide-dexamethasone in patients with relapsed/refractory multiple myeloma in TOURMALINE-MM1."],"pmcid":["PMC5622861"],"pubmed_authors":["Mateos MV","Hansson M","Borsaru G","Di Bacco A","Moreau P","Jackson SR","Hamadani M","Masszi T","Grzasko N","van de Velde H","Richardson PG","Stoppa AM","Berg D","Lin J","Pour L","Viterbo L","Sandhu I","Gimsing P"],"additional_accession":[]},"is_claimable":false,"name":"Impact of prior therapy on the efficacy and safety of oral ixazomib-lenalidomide-dexamethasone <i>vs</i>. placebo-lenalidomide-dexamethasone in patients with relapsed/refractory multiple myeloma in TOURMALINE-MM1.","description":"Prior treatment exposure in patients with relapsed/refractory multiple myeloma may affect outcomes with subsequent therapies. We analyzed efficacy and safety according to prior treatment in the phase 3 TOURMALINE-MM1 study of ixazomib-lenalidomide-dexamethasone (ixazomib-Rd) <i>versus</i> placebo-Rd. Patients with relapsed/refractory multiple myeloma received ixazomib-Rd or placebo-Rd. Efficacy and safety were evaluated in subgroups defined according to type (proteasome inhibitor [PI] and immunomodulatory drug) and number (1 <i>vs.</i> 2 or 3) of prior therapies received. Of 722 patients, 503 (70%) had received a prior PI, and 397 (55%) prior lenalidomide/thalidomide; 425 patients had received 1 prior therapy, and 297 received 2 or 3 prior therapies. At a median follow up of ~15 months, PF","dates":{"release":"2017-01-01T00:00:00Z","publication":"2017 Oct","modification":"2025-04-04T14:03:12.965Z","creation":"2019-07-24T07:12:28Z"},"accession":"S-EPMC5622861","cross_references":{"pubmed":["28751562"],"doi":["10.3324/haematol.2017.170118"]}}